March 22, 2022
CARLSBAD, Calif. , March 22, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced that the Company received a “Study May Proceed” letter from the U.S.
March 9, 2022
Company to Present Adhesions Prevention Data on Wednesday, March 16, 2022, at 8:30 a.m. ET CARLSBAD, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)
Displaying 11 - 18 of 18
Print Page
RSS Feeds
Email Alerts
Contact IR
Search